Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world.

BMJ Open Diabetes Res Care · 2019 · PMC6501856 · PMID 31114694

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Rates of documented symptomatic hypoglycemia with iGlarLixi were numerically lower versus iGlar in both NA and RoW patients in LixiLan-L and in NA patients in LixiLan-O, but these differences did not reach statistical significance ( figure 2 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.